Novartis: EU approves gene therapy to restore vision
(CercleFinance.com) - The European Commission has approved Luxturna, a one-time gene therapy for the treatment of people with rare inherited retinal disease, Novartis said on Friday.
The authorisation is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway.
Inherited retinal diseases are a group of rare blinding conditions caused by over 250 different genes, mostly affecting children and young adults.
These mutations affect approximately 1 in 200,000 people.
Luxturna was developed and is marketed in the US by Philadelphia-based startup Spark Therapeutics. Novartis owns marketing rights to Luxturna in countries other than the US.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The authorisation is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway.
Inherited retinal diseases are a group of rare blinding conditions caused by over 250 different genes, mostly affecting children and young adults.
These mutations affect approximately 1 in 200,000 people.
Luxturna was developed and is marketed in the US by Philadelphia-based startup Spark Therapeutics. Novartis owns marketing rights to Luxturna in countries other than the US.
Copyright (c) 2018 CercleFinance.com. All rights reserved.